Comprehensive Clinical Development, a US-based full-service contract research organisation (CRO) with particular expertise in Phase I and IIa trials, has become the first non-academic, non-hospital-based entity to join Quintiles’ global Prime Site network, set up to enhance local infrastructure for clinical studies.
The Prime Site designation builds on a longstanding relationship with Quintiles, noted Comprehensive, which said it would now have the opportunity to be “first in line” for any new industry-sponsored clinical trials taken on by its partner.
Comprehensive was chosen for its “deep experience in delivering high-quality data, rapid study start-up expertise and its access to substantial patient populations across multiple therapeutic areas, including psychiatry, oncology, neurology and endocrinology”, the Miramar, Florida-based company added.
Lindy Jones, Quintiles’ senior vice president, Integrated Site Services, cited Comprehensive’s “dedication to timeliness and quality, combined with their strong patient relationships and delivery quality”, which would enhance the biopharmaceutical service provider’s ability to recruit patients quickly and efficiently.
Comprehensive operates early-phase clinics in Miramar and in Tacoma, Washington state, as well as late-phase centres in Atlanta, Georgia; Cerritos, California; Queens, New York; St Petersburg, Florida; and Washington, D.C.